No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis

Détails

Ressource 1Télécharger: thèse-OK.pdf (6705.18 [Ko])
Etat: Public
Version: Après imprimatur
Licence: Non spécifiée
ID Serval
serval:BIB_5B211A93FC66
Type
Thèse: thèse de doctorat.
Collection
Publications
Titre
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
Auteur(s)
CLAUDE Fabien
Directeur(s)
HAFEN Gaudenz
Codirecteur(s)
AUBERT John-David
Détails de l'institution
Université de Lausanne, Faculté de biologie et médecine
Statut éditorial
Acceptée
Date de publication
2019
Langue
anglais
Résumé
Abstract
Objective: Patients with cystic fibrosis are more susceptible than members of the general population to lung infections.
Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period.
Results: Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature.
Création de la notice
23/08/2019 13:31
Dernière modification de la notice
24/09/2019 11:47
Données d'usage